Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
NOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€72.00 - €140.00
Previous CloseN/A
Volume1.40K
Average Volume (3M)1.45K
Market Cap
$315.74B
Enterprise Value€393.88B
Total Cash (Recent Filing)kr15.65B
Total Debt (Recent Filing)kr102.79B
Price to Earnings (P/E)23.9
Beta0.34
Next Earnings
May 07, 2025EPS Estimate
0.81Next Dividend Ex-Date
Mar 31, 2025Dividend Yield1.3%
Share Statistics
EPS (TTM)3.04
Shares Outstanding3,390,128,000
10 Day Avg. Volume1,199
30 Day Avg. Volume1,446
Financial Highlights & Ratios
PEG Ratio1.12
Price to Book (P/B)N/A
Price to Sales (P/S)10.92
Price to Cash Flow (P/CF)66.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€99.03Price Target Upside36.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Direct-to-consumer StrategyNovo has now established NovoCare Pharmacy enabling the company to directly ship Wegovy at all doses to patients at a discounted price.
Supply Chain ImprovementEnd of FDA shortage and establishment of NovoCare start to take steps to reclaim Novo's demand.
Bears Say
Market Differentiation ChallengeREDEFINE-2 misses an opportunity to differentiate in the obesity and diabetes market.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.56% Mutual Funds
5.17% Other Institutional Investors
93.13% Public Companies and
Individual Investors
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €72.00 and its highest was €140.00 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $315.74B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is May 07, 2025 which is in 56 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Feb 05, 2025. The company reported €0.816 earnings per share for the quarter, beating the consensus estimate of €0.765 by €0.051.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of €0.951 which represents an annual dividend yield of 1.3%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.81.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.816 in its last earnings report, beating expectations of €0.765. Following the earnings report the stock price went up 2.506%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
---
Novo Nordisk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€99.03 (36.02% Upside)
€99.03 (36.02% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 84%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.02%
12-Months-Change
Fundamentals
Return on Equity
82.03%
Trailing 12-Months
Asset Growth
38.79%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.
---
NOVA Company Deck
---
NOVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance and strategic growth in key areas such as GLP-1 treatments and obesity care, supported by significant R&D achievements. However, challenges remain with increased carbon emissions, supply constraints, and issues in the rare diseases segment. Despite these challenges, the positive developments in sales, profit, and R&D outcomes suggest more highlights than lowlights.Read More>---
NOVA Stock 12 Month Forecast
Average Price Target
€99.03
▲(36.02% Upside)
Technical Analysis
Best Analysts Covering NOVA
1 Year
1 Year Success Rate
8/23 ratings generated profit
1 Year Average Return
-0.68%
reiterated a buy rating 16 days ago
Copying Sachin Jain's trades and holding each position for 1 Year would result in 34.78% of your transactions generating a profit, with an average return of -0.68% per trade.
---